Additionally, PHH3 showed significant association with PFS after treatment with somatostatin analogues (HR 1.12 [1.03–1.21]), and borderline significant association with PFS after treatment with peptide receptor radionuclide therapy (HR 1.11 [1.00–1.24]).
← all excerpts
Phosphohistone H3 and Ki-67 as prognostic markers in metastatic small intestinal neuroendocrine tumours: A comparative, retrospective cohort study.
1
—
—